Teknova Reports First Quarter 2025 Financial Results
- Revenue increased 5% YoY to $9.8 million in Q1 2025
- Lab Essentials segment grew 12% YoY to $8.1 million
- Gross margin improved significantly to 30.7% from 23.8% YoY
- Net loss decreased to $4.6 million from $8.1 million YoY
- Secured exclusive manufacturing and distribution rights for PluriFreeze™ system
- Clinical Solutions revenue declined 32% YoY to $1.2 million
- Continued negative free cash flow of -$4.3 million in Q1
- Operating at a net loss despite revenue growth
Insights
Teknova shows modest 5% revenue growth with improved margins and reduced losses, but still operates at a deficit with cash concerns.
Teknova's Q1 2025 results reveal a company making operational improvements while still facing profitability challenges. Total revenue reached
The most significant improvement appears in gross margin, which expanded from
Net loss improved substantially to
The balance sheet shows
Management's reaffirmed
Teknova's exclusive PluriFreeze™ partnership strengthens position in cell therapy market while addressing critical preservation needs.
The announced collaboration with Pluristyx to bring their proprietary PluriFreeze™ cryopreservation system to market represents a strategic enhancement to Teknova's product portfolio. This system addresses a crucial technical challenge in the rapidly expanding cell therapy sector, where effective preservation of cellular materials is essential for maintaining viability throughout research, development, and eventual commercialization processes.
Induced Pluripotent Stem Cells (iPSCs) have emerged as foundational materials in next-generation cell therapies due to their versatility and differentiation potential. The technical challenges around preserving these cells during freeze-thaw cycles have been significant hurdles in the commercialization pathway. Effective cryopreservation systems that maintain cellular integrity and functionality are therefore high-value components in the cell therapy workflow.
By securing exclusive manufacturing and distribution rights for the PluriFreeze™ system in the US and Canada, Teknova positions itself as an integral supplier in the cell therapy value chain. The comprehensive nature of this product line, which includes both wash and storage components, provides developers with an integrated preservation solution rather than requiring them to piece together compatible reagents.
This partnership aligns perfectly with industry trends toward increased outsourcing of specialized reagents and processes in advanced therapy development. As clinical programs advance toward commercialization, regulatory requirements for standardized, high-quality preservation systems become more stringent, potentially creating sustained demand for validated solutions like PluriFreeze™.
While the financial impact of this collaboration wasn't quantified in the release, the strategic positioning is clear. This initiative should help Teknova strengthen relationships with cell therapy developers and potentially capture higher-margin business as these therapies progress toward commercialization.
First quarter 2025 total revenue was
Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.
Company reaffirms 2025 revenue guidance of
HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025.
“We delivered strong financial and operational results in the first quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Our ability to drive organic growth in such a highly uncertain macroenvironment is a testament to the criticality of our product portfolio and diversity of our customer base. We remain confident in our long-term outlook, particularly as our clinical customers advance their therapies towards commercialization.”
Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2025 compared to 2024, including
Corporate and Financial Updates
- First quarter 2025 total revenue of
$9.8 million , up5% from the first quarter 2024 - Entered into a collaboration with Pluristyx, Inc. – a leading provider of induced Pluripotent Stem Cells (iPSCs) – to expand access to their novel PluriFreeze™ cryopreservation system and to strengthen Teknova’s cell therapy product portfolio. Teknova is now the exclusive manufacturer and distributor of this proprietary product line, including wash and storage products, in the United States and Canada
- Total cash and short-term investments were
$26.3 million and total borrowings were$13.2 million at the end of the first quarter 2025
Revenue for the First Quarter 2025
| For the Three Months Ended March 31, | ||||||||
| (Dollars in thousands) | 2025 | 2024 | ||||||
| Lab Essentials | $ | 8,117 | $ | 7,266 | ||||
| Clinical Solutions | 1,162 | 1,718 | ||||||
| Other | 516 | 306 | ||||||
| Total revenue | $ | 9,795 | $ | 9,290 | ||||
First Quarter 2025 Financial Results
Total revenue for the first quarter 2025 was
Gross profit for the first quarter 2025 was
Operating expenses for the first quarter 2025 were
Net loss for the first quarter 2025 was
Adjusted EBITDA for the first quarter 2025 was negative
Reiterates 2025 Outlook
Teknova reiterates its fiscal 2025 outlook for revenue and free cash outflow. The Company continues to anticipate total revenue of
Upcoming Investor Conference Attendance
Sidoti Micro Cap Conference (Virtual)
May 21, 2025, at 11:30 a.m. Eastern Time
William Blair 45th Annual Growth Stock Conference (Chicago, IL)
June 4, 2025
Jefferies 2025 Global Healthcare Conference (New York, NY)
June 5, 2025, at 1:25 p.m. Eastern Time
Conference Call and Webcast
Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova continues to define Free Cash Flow as cash used in operating activities plus purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including expectations for 2025 revenue and free cash outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
| ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 9,795 | $ | 9,290 | ||||
| Cost of sales | 6,788 | 7,081 | ||||||
| Gross profit | 3,007 | 2,209 | ||||||
| Operating expenses: | ||||||||
| Research and development | 552 | 860 | ||||||
| Sales and marketing | 1,640 | 1,667 | ||||||
| General and administrative | 5,492 | 7,381 | ||||||
| Amortization of intangible assets | 287 | 287 | ||||||
| Total operating expenses | 7,971 | 10,195 | ||||||
| Loss from operations | (4,964 | ) | (7,986 | ) | ||||
| Other income (expenses), net | ||||||||
| Interest expense, net | (144 | ) | (145 | ) | ||||
| Other adjustment to loan exit fee | 485 | — | ||||||
| Total other income (expenses), net | 341 | (145 | ) | |||||
| Loss before income taxes | (4,623 | ) | (8,131 | ) | ||||
| Provision for (benefit from) income taxes | 22 | (34 | ) | |||||
| Net loss | $ | (4,645 | ) | $ | (8,097 | ) | ||
| Net loss per share—basic and diluted | $ | (0.09 | ) | $ | (0.20 | ) | ||
| Weighted average shares used in computing net loss per share—basic and diluted | 53,421,533 | 40,804,885 | ||||||
| ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) | ||||||||
| As of March 31, | As of December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,377 | $ | 3,708 | ||||
| Short-term investments, held -to-maturity | 22,896 | 26,688 | ||||||
| Accounts receivable, net | 5,616 | 4,312 | ||||||
| Inventories, net | 6,573 | 6,801 | ||||||
| Prepaid expenses and other current assets | 1,271 | 1,267 | ||||||
| Total current assets | 39,733 | 42,776 | ||||||
| Property, plant, and equipment, net | 44,728 | 45,753 | ||||||
| Operating right-of-use lease assets | 15,409 | 15,767 | ||||||
| Intangible assets, net | 12,804 | 13,091 | ||||||
| Other non-current assets | 1,319 | 1,382 | ||||||
| Total assets | $ | 113,993 | $ | 118,769 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,555 | $ | 825 | ||||
| Accrued liabilities | 3,640 | 4,541 | ||||||
| Current portion of operating lease liabilities | 1,850 | 1,800 | ||||||
| Current portion of long-term debt | — | 4,045 | ||||||
| Total current liabilities | 7,045 | 11,211 | ||||||
| Deferred tax liabilities | 848 | 827 | ||||||
| Other accrued liabilities | — | 10 | ||||||
| Long-term debt, net | 12,989 | 9,443 | ||||||
| Long-term operating lease liabilities | 14,506 | 14,884 | ||||||
| Total liabilities | 35,388 | 36,375 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | 1 | ||||||
| Additional paid-in capital | 201,780 | 200,924 | ||||||
| Accumulated deficit | (123,176 | ) | (118,531 | ) | ||||
| Total stockholders’ equity | 78,605 | 82,394 | ||||||
| Total liabilities and stockholders’ equity | $ | 113,993 | $ | 118,769 | ||||
| ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating activities: | ||||||||
| Net loss | $ | (4,645 | ) | $ | (8,097 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Bad debt expense | 45 | 7 | ||||||
| Inventory reserve | 437 | (91 | ) | |||||
| Depreciation and amortization | 1,580 | 1,636 | ||||||
| Stock-based compensation | 852 | 1,307 | ||||||
| Deferred taxes | 21 | (35 | ) | |||||
| Accrued interest income on short-term investments | (54 | ) | — | |||||
| Amortization of discount on short-term investments | (184 | ) | — | |||||
| Amortization of debt financing costs | 86 | 84 | ||||||
| Other adjustment to loan exit fee | (485 | ) | — | |||||
| Non-cash lease expense | 30 | 47 | ||||||
| Loss on disposal of property, plant, and equipment | — | 49 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,349 | ) | (619 | ) | ||||
| Inventories | (209 | ) | 478 | |||||
| Prepaid expenses and other current assets | (4 | ) | 174 | |||||
| Other non-current assets | 63 | 117 | ||||||
| Accounts payable | 740 | 133 | ||||||
| Accrued liabilities | (1,017 | ) | (1,724 | ) | ||||
| Other | (10 | ) | (24 | ) | ||||
| Cash used in operating activities | (4,103 | ) | (6,558 | ) | ||||
| Investing activities: | ||||||||
| Purchases of short-term investments | (1,970 | ) | — | |||||
| Maturities of short-term investments | 6,000 | — | ||||||
| Proceeds from sale of property, plant, and equipment | — | 125 | ||||||
| Purchases of property, plant, and equipment | (206 | ) | (112 | ) | ||||
| Cash provided by investing activities | 3,824 | 13 | ||||||
| Financing activities: | ||||||||
| Proceeds from long-term debt | 1,110 | — | ||||||
| Payment of exit fee costs | (1,110 | ) | — | |||||
| Payments related to equity financing | — | (37 | ) | |||||
| Repayment of financed insurance premiums | (56 | ) | (306 | ) | ||||
| Proceeds from exercise of stock options | 4 | — | ||||||
| Cash used in financing activities | (52 | ) | (343 | ) | ||||
| Change in cash and cash equivalents | (331 | ) | (6,888 | ) | ||||
| Cash and cash equivalents at beginning of period | 3,708 | 28,484 | ||||||
| Cash and cash equivalents at end of period | $ | 3,377 | $ | 21,596 | ||||
| ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net loss – as reported | $ | (4,645 | ) | $ | (8,097 | ) | ||
| Add back: | ||||||||
| Interest expense, net | (144 | ) | (145 | ) | ||||
| Provision for (benefit from) income taxes | 22 | (34 | ) | |||||
| Depreciation expense | 1,293 | 1,349 | ||||||
| Amortization of intangible assets | 287 | 287 | ||||||
| EBITDA | $ | (2,899 | ) | $ | (6,350 | ) | ||
| Other and non-recurring expenses: | ||||||||
| Stock-based compensation expense | 852 | 1,307 | ||||||
| Severance pay and other termination benefits | — | 1,287 | ||||||
| Other adjustment to loan exit fee | (485 | ) | — | |||||
| Adjusted EBITDA | $ | (2,532 | ) | $ | (3,756 | ) | ||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash used in operating activities | $ | (4,103 | ) | $ | (6,558 | ) | ||
| Purchases of property, plant, and equipment | (206 | ) | (112 | ) | ||||
| Free Cash Flow | $ | (4,309 | ) | $ | (6,670 | ) | ||
This press release was published by a CLEAR® Verified individual.
FAQ
What was Teknova's (TKNO) revenue growth in Q1 2025?
What is Teknova's revenue guidance for 2025?
What was TKNO's gross margin in Q1 2025?
What is the PluriFreeze collaboration announced by Teknova?
How much did Teknova's Lab Essentials segment grow in Q1 2025?
